NANOBIOTIX Reports First Half 2026 Operational and Financial Results
NANOBIOTIX, a late-clinical stage biotechnology company specializing in nanotherapeutics for cancer and other major diseases, announced its operational progress and financial results for the first half of 2026. The update was released on September 24, 2026, highlighting the company's advancements and financial performance during this period.
Financialcontent·


